Pharmafile Logo

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

November 11, 2024 |  

OPEN Health is excited to announce the upcoming presentation of a collection of research supported by its Scientific Buyout Program. This initiative empowers our team members to dedicate time toward innovative projects in HEOR and market access. We’re proud to invest in our team’s growth and scientific excellence.

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

London, Nov 11, 2024 — OPEN Health, a preeminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting services, today announced the upcoming presentation of a collection of research supported by its Scientific Buyout Program. The Scientific Buyout Program initiative allows staff members to “buy out” time from their regular duties to engage in important scientific projects, including developing manuscripts, exploring new methodologies, conducting research, and preparing conference presentations.

“Our Scientific Buyout Program reflects our dedication to fostering a culture of scientific excellence and collaboration,” said Professor Ben van Hout, Scientific Founder, OPEN Health HEOR & Market Access. “By providing the opportunity to focus on self-chosen projects, we aim to enhance our contributions to the HEOR and market access fields while encouraging professional development within our team.”

The program runs in three rounds each year, with the first two rounds in 2024 already demonstrating significant participation and promising outcomes. In total, 83 scientists across OPEN Health submitted their project proposals, resulting in 26 projects shortlisted and presented to the Scientific Office. Ultimately, 65% of projects were accepted and funded, highlighting that the time allocation provided through the initiative further drives advanced research.

As a result, OPEN Health is proud to announce that 12 presentations will be made at two international conferences in 2024, including 9 posters at the prestigious ISPOR EU conference in Barcelona. The posters cover the key topics of the conference including the use and acceptability of AI in HTA, patient engagement in HTA, and EU HTA processes, among others, and will feature the “Funded by the Scientific Office” stamp, emphasizing the support behind these projects.

Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, added, “This program not only empowers our scientists but also fosters a collaborative environment where new ideas can thrive. We believe that investing in our scientific talent is crucial for driving progress in healthcare.”

For more information about the Scientific Buyout Program and OPEN Health’s commitment to scientific advancement, please visit https://www.openhealthgroup.com/what-we-do/heor-market-access/

 

About OPEN Health: OPEN Health unites world-class scientific, strategic, and creative expertise to solve complex challenges for global biopharma. We are a flexible, global organization, creating high-performing strategic partnerships with our clients. We embrace our different perspectives and strengths to deliver innovative solutions that have a positive impact on commercial and patient outcomes. OPEN Health unlocks possibilities across consulting, HEOR and market access, scientific communications, and patient engagement. To learn more, visit www.openhealthgroup.com.

Contact:

Candice Subero

OPEN Health

candicesubero@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa

Ben Speller shares his thoughts on the value of disease specific congresses

OPEN Health use PR to support clinical trial recruitment

International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2

OPEN Health | European Congress on Rare Diseases (ECRD) 2020 in 60 seconds

Gavin Jones, Director or Rare Disease, attends the congress to better understand the viewpoints of patient groups, health systems and payers

OPEN Health attend day 2 of the ECRD2020 congress

Gavin Jones is looking forward to sessions on innovation in advanced therapies and working towards equitable access.

OPEN Health continued support for My Name’5 Doddie

Charity fundraising for Motor Neuron Disease

OPEN Health’s latest partnership with Rare Revolution Magazine

Richard Jones introduces our Head of Health Psychology (Dr Sumira Riaz)

OPEN Health CSR Report 2019

Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.

OPEN Health at ECRD 2020

Gavin Jones shares his thoughts on why congress is so important at this time and the key sessions he is looking forward to.

OPEN Health discuss Global Community in Rare Disease

Annie Rankin how we can work smarter with healthcare professionals

OPEN Health Patient & Brand Communications highly commended finalist

Shortlisted for Best Patient-Centric Approach for 2020 BOBI Awards.